Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma

Liu, Man, Zhou, Jingying, Liu, Xiaoyu, Feng, Yu, Yang, Weiqin, Wu, Feng, Cheung, Otto Ka-Wing, Sun, Hanyong, Zeng, Xuezhen, Tang, Wenshu, Mok, Myth T S, Wong, John, Yeung, Philip Chun, Lai, Paul Bo San, Chen, Zhiwei, Jin, Hongchuan, Chen, Jie, Chan, Stephen Lam, Chan, Anthony W H, To, Ka Fai, Sung, Joseph J Y, Chen, Minhu, Cheng, Alfred Sze-Lok·2020·Gut

Abstract

Objective: Hepatocellular carcinoma (HCC), mostly developed in fibrotic/cirrhotic liver, exhibits relatively low responsiveness to immune checkpoint blockade (ICB) therapy. As myeloid-derived suppressor cell (MDSC) is pivotal for immunosuppression, we investigated its role and regulation in the fibrotic microenvironment with an aim of developing mechanism-based combination immunotherapy. Design: Functional significance of MDSCs was evaluated by flow cytometry using two orthotopic HCC models in fibrotic liver setting via carbon tetrachloride or high-fat high-carbohydrate diet and verified by clinical specimens. Mechanistic studies were conducted in human hepatic stellate cell (HSC)-peripheral blood mononuclear cell culture systems and fibrotic-HCC patient-derived MDSCs. The efficacy of single or combined therapy with anti-programmed death-1-ligand-1 (anti-PD-L1) and a clinically trialled BET bromodomain inhibitor i-BET762 was determined. Results: Accumulation of monocytic MDSCs (M-MDSCs), but not polymorphonuclear MDSCs, in fibrotic livers significantly correlated with reduced tumour-infiltrating lymphocytes (TILs) and increased tumorigenicity in both mouse models. In human HCCs, the tumour-surrounding fibrotic livers were markedly enriched with M-MDSC, with its surrogate marker CD33 significantly associated with aggressive tumour phenotypes and poor survival rates. Mechanistically, activated HSCs induced monocyte-intrinsic p38 MAPK signalling to trigger enhancer reprogramming for M-MDSC development and immunosuppression. Treatment with p38 MAPK inhibitor abrogated HSC-M-MDSC crosstalk to prevent HCC growth. Concomitant with patient-derived M-MDSC suppression by i-BET762, combined treatment with anti-PD-L1 synergistically enhanced TILs, resulting in tumour eradication and prolonged survival in the fibrotic-HCC mouse model. Conclusion: Our results signify how non-tumour-intrinsic properties in the desmoplastic microenvironment can be exploited to reinstate immunosurveillance, providing readily translatable combination strategies to empower HCC immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2018-317257

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 176

Metadata

Authors
Liu, M., Zhou, J., Liu, X., Feng, Y., Yang, W., Wu, F., Cheung, O. K.-W., Sun, H., Zeng, X., Tang, W., Mok, M. T. S., Wong, J., Yeung, P. C., Lai, P. B. S., Chen, Z., Jin, H., Chen, J., Chan, S. L., Chan, A. W. H., To, K. F., Sung, J. J. Y., Chen, M., & Cheng, A. S.-L.
Venue
Gut
Publisher
BMJ
Published
2019-05-10
Volume
69
Issue
2
Pages
365-379
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2944601575
Cited by
176
References
14
FWCI
7.13
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. https://app.cochat.ai/papers/10.1136/gutjnl-2018-317257
The paper
Liu, M., Zhou, J., Liu, X., Feng, Y., Yang, W., Wu, F., Cheung, O. K.-W., Sun, H., Zeng, X., Tang, W., Mok, M. T. S., Wong, J., Yeung, P. C., Lai, P. B. S., Chen, Z., Jin, H., Chen, J., Chan, S. L., Chan, A. W. H., . . . Cheng, A. S.-L. (2020). Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut. https://doi.org/10.1136/gutjnl-2018-317257

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.